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Background. Although rates of sustained virologic response (SVR) after hepatitis C virus (HCV) treatment with direct-acting 
antivirals (DAAs) surpass 90% in trials and some more “real world” settings, some patients, such as those with substance use disor-
ders, will be challenged to adhere to HCV care.
Methods. To assess the feasibility of 2 strategies for financially incentivizing adherence to HCV care, patients with a substance 
use history prescribed 12 weeks of a sofosbuvir-containing regimen were randomized to either fixed or lottery-based monetary 
incentives for attending clinic appointments, pill count adherence >90%, and SVR achievement. Electronic medication monitoring 
provided an objective measure of DAA adherence.
Results. Fifty-nine participants were randomized to the lottery (n = 31) or fixed-incentive (n = 28) arms. All 31 (100%) in the 
lottery arm and 24 of 28 (86%) in the fixed arm completed 12 weeks of therapy. By intent-to-treat, 93% in the lottery arm and 92% 
in the fixed arm achieved SVR (estimated difference: 0.5%; 95% confidence interval, −17.5 to 18.8). Overall, 92% of scheduled visits 
were attended without significant differences between arms. The mean adherence ratio (days with ≥1 bottle opening:monitored 
days) was 0.91 for lottery and 0.92 for fixed arms.
Conclusions. In this pilot, fixed- and lottery-based financial incentives were successfully implemented and accepted by patients 
with a substance use history. High levels of HCV therapy and care adherence, as well as rates of SVR, were observed. Financial 
incentives may be useful to support treatment adherence in patients with substance use disorders and should be tested in a larger, 
randomized, controlled trial.
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Direct-acting antivirals (DAAs) have revolutionized the man-
agement of hepatitis C virus (HCV) infection, the most prev-
alent chronic bloodborne pathogen in the United States. With 
sustained virologic response (SVR) rates of 85%–95%, these 
medications are potent but also very well tolerated and conveni-
ent, and the usual course of treatment is often 12 weeks [1–6].
In clinical trials and observational studies, failure to respond 
to DAA regimens has been ascribed to a number of factors 
including drug-drug interactions, host genetics, and inherent 
viral drug resistance [7, 8]. However, medication adherence has 
also been implicated in suboptimal HCV treatment outcomes, 
and, as the number of real-world patients who receive treatment 
increases, there are concerns that rates of virologic response will 
be lower than those observed in clinical research studies [9–15]. 
In particular, there are questions regarding the ability of those 
with substance abuse disorders to adhere to a full-course HCV 
therapy, given the social instability and mental health challenges 
that frequently characterize the lives of these individuals [14–16].
Studies conducted in the pre-DAA era examining an asso-
ciation between substance use and HCV treatment outcomes 
such as adherence, treatment discontinuation, and virologic 
response have produced mixed results [16]. Data regarding 
adherence to the newest DAAs are sparse. Pill count and elec-
tronic medication assessments during DAA clinical trials have 
found high adherence levels, even among the few participants 
with active substance use or who were receiving opioid substitu-
tion therapy [17–19]. To participate in clinical research studies, 
patients must meet criteria that are designed to exclude those at 
the highest risk of nonadherence, including heavy users of illicit 
substances. In one analysis, less than 10% of patients living with 
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HCV infection in Canada would meet eligibility criteria of 4 of 
the 5 major clinical trials that, by the end of 2015, had led to 
second-generation DAA approval, with most patients excluded 
due to active illicit substance use [20].
Observational studies examining prescription refills among 
HCV-infected patients receiving community care also demon-
strate high rates of adherence to newer DAA regimens [21, 
22]. Sustained virologic response rates approximating those 
reported from clinical trials have also been observed in such 
studies [21–23]. However, although such “real-world” experi-
ences are encouraging, these studies are also not without poten-
tial selection bias. Clinicians often are restrictive in their criteria 
for treatment eligibility, and many continue to deem patients 
with active substance use and mental health disorders as poor 
candidates for HCV therapy. Moreover, some state Medicaid 
programs make approval of HCV therapy coverage contin-
gent upon months of documentation abstinence. An analysis 
of HCV treatment outcome data from over 4000 patients in 
the Veterans Administration system, which generally has less 
restrictive criteria for HCV therapy, found SVR rates that were 
lower than those seen in clinical trials [11].
Expanding HCV therapy to “all-comers” will lead to the treat-
ment of a greater number of patients who may have difficulty 
adhering to medication and clinic visits [14–16]. Although the 
proportion of the estimated 4 million HCV-infected persons 
in the United States who may be suboptimally adherent to a 
DAA regimen is relatively small, the absolute number of such 
patients and the costs of treatment failure are not. At present, 
there is a limited evidence base on interventions that can sup-
port adherence to these medications, especially for individuals 
challenged with chronic or active substance use disorders [24], 
and although there have been calls by some HCV care providers 
for the integration of HCV care within primary care clinics and 
addiction treatment centers, models of such programs remain 
untested in controlled studies [25, 26].
In contrast, an approach that has been demonstrated in ran-
domized, controlled trials to positively influence health behav-
iors is financial incentivization [27–39]. Financial incentives 
using various strategies have been applied to promote weight 
loss, smoking cessation, tuberculosis treatment, and antiretro-
viral therapy [27–30]. Such incentivization may be effective not 
only through offsetting the cost of clinic attendance for patients 
but also by offering immediate rewards for behaviors that other-
wise have a delayed benefit [37]. In particular, financial incentive 
interventions have proven especially potent for achieving and 
maintaining sobriety and abstinence from substance use [30–39].
In this pilot study, we explored the feasibility of implementing 
financial incentives for DAA and clinic visit adherence among 
HCV-infected men and women with a history of substance use. 
Two commonly used strategies—fixed versus lottery-based 
incentives—on adherence to DAA adherence, routine HCV 
clinical care visits, and achievement of SVR were studied.
METHODS
Study Design and Participants
Participants in this single-center, randomized clinical trial were 
individuals age 18  years or greater with documented chronic 
HCV infection (HCV seropositive and detectable plasma HCV 
ribonucleic acid [RNA]) who were prescribed a 12-week course 
of a sofosbuvir-based HCV therapy regimen. At the time the 
study was developed and launched, sofosbuvir was the most 
commonly prescribed second-generation DAA approved for 
use in the United States. All participants had to self-report a 
history of substance use for at least 1 year in their lifetime, be 
English-speaking, and be able and willing to provide informed 
consent. All participants were patients of either the University 
of North Carolina (UNC) Infectious Diseases Clinic or Liver 
Center. Data were collected during routine clinic visits for HCV 
care. Hepatitis C virus treatment was selected by the partici-
pant’s clinician before study referral and entry/randomization. 
The research protocol, consent documents, and recruitment 
materials were approved by the UNC Institutional Review 
Board.
Study Arms
After consent, participants were randomized 1:1 to 1 of 2 study 
arms: either fixed or lottery-based financial incentives to rein-
force clinic attendance and medication adherence. The incen-
tive amount was chosen to offset clinic transportation costs 
as well as lost wages and also to appear large enough to moti-
vate health-seeking behavior. Those in the fixed-incentive arm 
received $40 for each scheduled HCV-related clinic appoint-
ment attended (or if rescheduled within 5 business days of their 
original appointment) and $20 for HCV medication pill count 
adherence of >90%. A bonus of $50 was provided for achieve-
ment of an undetectable HCV viral load at the end of treatment 
(EOT) and at 12 weeks postcompletion of treatment (ie, SVR). 
Incentives provided in the lottery-based incentive arm occurred 
on the same schedule as fixed incentives and for the same mile-
stones. However, participants in this arm were asked to draw a 
card from a bag to determine the amount they received for each 
milestone. Cards were printed with one of the following val-
ues: $10, $30, and $100. Participants who qualified for a clinic 
attendance lottery draw chose 1 card from a bag that contained 
cards with the following probabilities: 20% for $100, 30% for 
$30, and 50% for $10. Participants who qualified for a pill count 
adherence lottery draw chose 1 card from a bag that contained 
cards with the following probabilities: 10% for $50, 40% for $20, 
and 50% for $10. A  bonus of 2 lottery draws from the clinic 
attendance bag was provided for achievement of an undetect-
able HCV viral load at EOT and SVR. For both study arms, all 
financial incentives were provided in the form of cash and paid 
immediately, except for the incentive based on the achievement 
of SVR, which was paid after return of the determining HCV 
RNA result.
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Assessments and Outcomes
After the baseline visit, study visits were conducted on the same 
day that participants came for their routinely scheduled HCV-
related clinic appointments. These routine visits generally were 
scheduled monthly during the 12 weeks of active HCV therapy 
and then at EOT and 12 weeks posttreatment.
Surveys and Record Review
At baseline, demographic information, medical history, self-re-
ported alcohol and substance use (Alcohol Use Disorders 
Identification Test [AUDIT] [40], Drug Abuse Screen Test 
[DAST] [41], Texas Christian University Drug Screen-II [42]), 
and depression screening (Center for Epidemiologic Studies 
Depression Scale [CES-D] [43]) responses were collected by 
a research assistant via computer-assisted participant inter-
viewing (CAPI) using a web-based survey platform (Qualtrics, 
Provo, UT). At subsequent visits, alcohol, substance use, and 
depression surveys were administered. Medical records were 
reviewed to confirm clinic visit attendance and laboratory 
results. At the last study visit, semistructured interviews were 
conducted among 15 participants to obtain their perspectives 
regarding HCV treatment and the financial incentive strategy 
to which they were assigned.
Medication Adherence
Adherence to HCV medications was assessed using electronic 
medication monitoring (MEMSCap; WestRock Switzerland, 
Ltd) and pill count. For each participant, an electronic monitor-
ing device was placed on her/his sofosbuvir-containing medi-
cation bottle. The cap recorded the time and date of each bottle 
opening, and these data were downloaded at each visit during 
the treatment course. Participants were asked at each visit about 
use of the electronic cap, including diversion of pills from the 
monitored bottle to other containers or pill boxes. Cap opening 
data were used as a measure of medication adherence and were 
not shared with the participant, nor were cap data used to trig-
ger financial incentives. For pill counts, the number of tablets 
in each bottle of oral HCV medication were counted and the 
proportion of tablets present was compared with the proportion 
expected. The resultant ratio was categorized as <90% (subopti-
mal adherence), 90%–100% (optimal adherence), >100% (over 
adherence).
Plasma Hepatits C Virus Ribonucleic Acid
Quantitative HCV RNA measurements were conducted accord-
ing to standard of care as determined by the participants’ clini-
cians. Testing was conducted at the UNC McLendon Clinical 
Laboratories or commercial clinical laboratories, and results 
were abstracted from electronic medical records. An HCV RNA 
level obtained >8 weeks after completion of therapy was used to 
determine achievement of SVR.
Urine Toxicology Screening
At baseline and subsequent visits, participants were asked to 
provide urine to screen for the presence of cocaine, opiates, 
benzodiazepines, and amphetamines not expected to be present 
based on self-reported and medical record medication lists.
Statistical Methods
The primary aim of this study was to assess the feasibility of 
fixed versus lottery-based financial incentives to improve 
adherence to DAAs and to attendance at treatment-related vis-
its among HCV-infected patients with a substance use history. 
Feasibility was assessed by describing successful implementa-
tion of the interventions, study retention rates, and the comple-
tion of study assessments.
Medication adherence was assessed using pill count and elec-
tronic cap data as a secondary outcome. For electronic cap data, 
when the number of bottle openings matched or exceeded the 
expected dose frequency, adherence for the day was considered 
a success. An adherence ratio was calculated as the number of 
successful adherence days divided by the number of monitored 
days; HCV DAAs were prescribed to be taken once daily. The 
overall proportion of participants with an electronic cap adher-
ence level ≥90% and the difference in proportions between 
arms was estimated with a corresponding exact Chan and 
Zhang [44] 95% confidence interval (CI). Electronic cap data 
were analyzed using 2 approaches: (1) a conservative analysis 
in which no adjustment to the recorded data were made and (2) 
an adjudicated analysis in which the electronic cap data were 
censored based on participant self-report of nonuse of the cap.
An additional secondary aim of this study was to determine 
the proportion of participants who achieved SVR. An intent-
to-treat (ITT) analysis was complete-case and included all par-
ticipants who were randomized and who had an HCV RNA 
level obtained >8 weeks after the treatment regimen ended. 
A per-protocol (PP) analysis was also conducted and included 
participants in the ITT analysis sample who completed a 
12-week regimen, but unlike the ITT analysis it excluded par-
ticipants (n  =  5) whose treatment durations were modified 
during the study to either an 8- or 24-week course. The overall 
proportion of participants who achieved SVR was estimated 
with a corresponding exact Clopper-Pearson 95% CI [45]. The 
proportion of participants in each study arm who achieved SVR 
was calculated, and the difference in proportions between arms 
was estimated with a corresponding exact Chan and Zhang [44] 
95% CI.
The effect of substance use on the outcomes of interest was 
examined by the following: (1) estimating the proportion ratio 
(PR) for achievement of SVR among participants whose last 
on-study urine samples tested positive for substances of abuse 
versus those participants who tested negative for these sub-
stances and (2) estimating the PR for achievement of an adju-
dicated adherence level of ≥90% for those whose baseline urine 
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sample tested positive for substances of abuse versus those who 
tested negative. The last urine toxicology screen was used in 
the SVR analysis to represent substance use during the study 
period while minimizing missing data, and the baseline urine 
screen was used in the adherence analysis to measure sub-
stance use near the start of HCV treatment. Participants were 
excluded from these analyses if they were missing the relevant 
urine screen data, final SVR status, or adherence status. The 
PR was estimated with a corresponding exact Chan and Zhang 
[44] 95% CI. All statistical analyses were conducted in SAS ver-
sion 9.4 (SAS Institute, Cary, NC) or StatXact-11 (Cytel, Inc., 




Seventy patients were consented, screened, and entered into 
the trial (Figure 1). Of these, 11 were not enrolled, mostly due 
to an inability to receive payer approval for coverage of their 
prescribed DAA regimen. The remaining 59 participants were 
randomized to the lottery-based (n  =  31) or fixed incentive 
(n  =  28) study arms. The majority (68%) of the participants 
were men and the median age was 54 years; half were nonwhite 
(Table  1). One third (32%) were known to be human immu-
nodeficiency virus-coinfected, and 41% had a diagnosis of 
cirrhosis documented in the medical record. At baseline, 46% 
reported that they were actively using illicit substances. The 
CES-D scores indicated that clinical depression was prevalent, 
with 71% scoring above 16, a threshold used to indicate pres-
ence of clinical depression. Six (10%) of the particiants were 
classified at baseline as engaging in hazardous drinking based 
on an AUDIT score of 8 or greater. Hepatitis C virus genotype 
1 accounted for 90% of the infections. Approximately half the 
participants (47%) were prescribed the single tablet formulation 
of ledipasvir/sofosbuvir.
All 31 (100%) of those assigned to the lottery arm and 24 
of 28 (86%) assigned to the fixed-incentive arm completed a 
12-week course of therapy (Figure 1). Of the 4 who did not, 3 
had their treatment duration extended to 24 weeks by the clini-
cian (independent of virologic response or adherence concerns) 




31 assigned to Lottery
incentive
28 evaluable for SVR
26 achived SVR 24 achived SVR*
26 evaluable for SVR
3 without SVR determination
2 lost to follow-up
1 without HCV RNA
2 with detectable HCV RNA
1 <12 c/mL but detectable
1 >12 c/mL 
2 with detectable HCV RNA
1 <12 c/mL but detectable
1 >12 c/mL
2 without SVR determination
1 lost to follow-up
1 died before SVR visit
28 assigned to Fixed
incentive
11 were ineligible
8 never received HCV medications
2 prescribed 24 weeks of  HCV therapy
1 did not respond to invitation
Figure 1. Screening, randomization, and follow-up analyses. HCV, hepatitis C virus; RNA, ribonucleic acid; SVR, sustained virologic response.
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and 1 was only able to receive 8 weeks of therapy because the 
payer would not approve the planned final 4 weeks.
After completion of treatment, 2 of 31 participants (6%) in 
the lottery arm and 1 of 28 (4%) in the fixed-incentive arm were 
lost to follow-up before ascertainment of SVR. In addition, 1 
participant in the lottery arm did not have an SVR measure-
ment (HCV RNA at 8 weeks posttreatment was undetetcable), 
and in the fixed-incentive group 1 participant died of carcinoma 
of the lung before the planned SVR visit.
Financial Incentives
The mean financial incentive per visit provided to participants 
was $71 (standard deviation [SD] = $18) in the lottery arm and 
$67 (SD = $9) in the fixed-incentive arm. The mean total finan-
cial incentive received was $259 (SD = $74) in the lottery arm 
and $239 (SD = $58) in the fixed-incentive arm.
Perceptions Regarding Financial Incentives
Fifteen participants (8 in the fixed-incentive arm and 7 from 
lottery arm) completed a semistrucutred qualitative interview. 
Participants expressed general satisfaction with their assigned 
incentive strategy. The majority of the fixed-incentive arm par-
ticipants states they preferred the dependability of a predeter-
mined amount and appreciated knowing how much they would 
receive for completing treatment objectives. Those randomized 
to the lottery generally found this strategy to be “fun,” and they 
Table 1. Participant Characteristics
Lottery Fixed Overall
Sex, n 31 28 59
Male 23 (74%) 17 (61%) 40 (68%)
Female 8 (26%) 11 (39%) 19 (32%)
Ethnicity, n 31 28 59
Hispanic/Latino 0 (0%) 1 (4%) 1 (2%)
Other 31 (100%) 27 (96%) 58 (98%)
Race, n 31 28 59
White/Caucasian 18 (58%) 11 (39%) 29 (49%)
Black/African American 12 (39%) 13 (46%) 25 (42%)
Indian (American) 0 (0%) 1 (4%) 1 (2%)
Mixed 1 (3%) 2 (7%) 3 (5%)
Latin 0 (0%) 1 (4%) 1 (2%)
Age (years), n 31 28 59
Median (Q1, Q3) 55 (50, 60) 54 (50, 58) 54 (50, 60)
Mean (SD) 55 (9) 53 (10) 54 (9)
Income, n 31 28 59
$0–$20 000 24 (77%) 17 (61%) 41 (69%)
$21 000–$40 000 3 (10%) 5 (18%) 8 (14%)
$41 000–$60 000 4 (13%) 1 (4%) 5 (8%)
$61 000–$80 000 0 (0%) 1 (4%) 1 (2%)
Refused 0 (0%) 4 (14%) 4 (7%)
Highest Level of Education, n 30 28 58
No. missing 1 0 1
Middle school (Jr. High) or less 4 (13%) 0 (0%) 4 (7%)
Some high school, no diploma 7 (23%) 5 (18%) 12 (21%)
High school graduate/GED or 
equivalent
11 (37%) 12 (43%) 23 (40%)
Junior (2 year) college 1 (3%) 1 (4%) 2 (3%)
Technical/trade/vocational school 0 (0%) 3 (11%) 3 (5%)
Some college (4-year college or 
university)
3 (10%) 5 (18%) 8 (14%)
College graduate (4-year college or 
university
2 (7%) 1 (4%) 3 (5%)
Postcollege/graduate 1 (3%) 1 (4%) 2 (3%)
Don’t know 1 (3%) 0 (0%) 1 (2%)
Health Insurance Status, n 31 28 59
Insured 25 (81%) 21 (75%) 46 (78%)
Uninsured 6 (19%) 7 (25%) 13 (22%)
Housing Statusa, n 31 28 59
Stable 18 (58%) 21 (75%) 39 (66%)
Unstable 13 (42%) 7 (25%) 20 (34%)
HCV-RNA (log10 IU/mL), n 31 27 58
No. missing 0 1 1






Mean (SD) 6.14 (0.75) 5.95 (0.69) 6.05 (0.72)
Liver Cirrhosis, n 31 28 59
Yes 11 (35%) 13 (46%) 24 (41%)
No 19 (61%) 15 (54%) 34 (58%)
Unknown 1 (3%) 0 (0%) 1 (2%)
HCV Genotype, n 31 28 59
1 26 (84%) 27 (96%) 53 (90%)
2 5 (16%) 1 (4%) 6 (10%)
Documented HIV Status, n 31 28 59
Positive 9 (29%) 10 (36%) 19 (32%)
Negative 11 (35%) 10 (36%) 21 (36%)
Unknown 11 (35%) 8 (29%) 19 (32%)
CES-D Score, n 31 28 59
Lottery Fixed Overall
Median (Q1, Q3) 22 (17, 30) 19 (15, 25) 21 (15, 27)
Mean (SD) 24 (10) 21 (9) 23 (10)
Current Drug-Use Statusb, n 31 28 59
Active 12 (39%) 15 (54%) 27 (46%)
Not Active 19 (61%) 13 (46%) 32 (54%)
Current Drug(s) Used, n 31 28 59
Marijuana 11 (35%) 10 (36%) 21 (36%)
Hallucinogens 2 (6%) 1 (4%) 3 (5%)
Cocaine/crack 5 (16%) 7 (25%) 12 (20%)
Heroin 2 (6%) 2 (7%) 4 (7%)
Street methadone 0 (0%) 1 (4%) 1 (2%)
Prescription painkillersc 1 (3%) 7 (25%) 8 (14%)
Methamphetamines 2 (6%) 0 (0%) 2 (3%)
Stimulants 2 (6%) 1 (4%) 3 (5%)
Tranquilizers/sedatives 1 (3%) 1 (4%) 2 (3%)
Regimen, n 31 28 59
Ledipasvir/sofosbuvir 14 (45%) 14 (50%) 28 (47%)
Ribavirin, ledipasvir/sofosbuvir 1 (3%) 0 (0%) 1 (2%)
Ribavirin, sofosbuvir 5 (16%) 1 (4%) 6 (10%)
Ribavirin, sofosbuvir, interferon 3 (10%) 1 (4%) 4 (7%)
Ribavirin, sofosbuvir, simeprevir 1 (3%) 1 (4%) 2 (3%)
Sofosbuvir, simeprevir 7 (23%) 11 (39%) 18 (31%)
Abbreviations: CES-D, Center for Epidemilogical Studies Depression; GED, General 
Education Diploma; HCV, hepatitis C virus; HIV, human immunodeficiency virus; RNA, ribo-
nucleic acid; SD, standard deviation.
aHousing stability was defined as owning or renting a house or apartment.
bCurrent was defined to be in the past month.
cNarcotics available by prescription.
Table 1. Continued
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stated that they liked the chance involved, comparing it to being 
at “the fair.” When asked which incentive strategy to offer future 
patients, 75% of the fixed-incentive arm interviewees recom-
mended the fixed-incentive, and 71% of the lottery arm inter-
viewees recommended the lottery.
Hepatitis C Virus Study Visit and Medication Adherence
Rates of attendance of scheduled clinic visits for HCV care are 
listed in Table 2. Overall, 92% of scheduled visits were attended 
(including 95% of the week 12 EOT visits and 88% of SVR 
visits), and there was no statistically significant difference in 
missed visits between the study arms. Both the median and 
mean number of clinic visits attended was 4 in each study arm 
(for both lottery and fixed incentives; SD = 1).
Electronic medication monitoring estimated a mean adher-
ence ratio (days with ≥1 bottle opening:monitored days) of 
0.91 overall (0.91 for lottery and 0.92 for fixed incentive) in 
the adjudicated analysis, excluding those without reliable cap 
data (eg, those who used a pill box) (Figure  2). Adherence 
of 90% or greater as estimated by electronic monitoring was 
achieved by 72.4% of particiants including 70% of the lottery 
and 75% of fixed incentive participants (estimated difference 
of −5.0%; exact 95% CI, −28.2 to 19.1). Adherence results were 
very similar in the conservative, unadjudicated analysis (data 
not shown). Participants brought medication bottles to 85% of 
scheduled clinic visits for pill counts, and less than 10% had 
estimated adherence fall below 90% at any monthly visit.
Rates of Sustained Virologic Response 
In the ITT analysis, 92.9% of the lottery arm and 92.3% of the 
fixed-incentive arm achieved SVR (estimated difference of 
0.5%; 95% CI, −17.5 to 18.8). The PP analysis yielded similar 
results (Table 3).
Substance Use Screening at Baseline, During and After Hepatitis C Virus 
Treatment
Fifty-five of 59 participants (93%) had at least 1 urine speci-
men submitted for toxicology. At baseline, 10 of 48 (21%; 19% 
of lottery, 23% of fixed) providing urine screened positive for 
substances of abuse. During the trial, a positive toxicology 
screen was detected at least once in 31% of the 55 participants 
providing a urine sample, balanced evenly between the lottery 
(9 of 29) and fixed-incentive (8 of 26) arms. At the last visit at 
which a urine specimen was provided, 14 of the 55 (25%) par-
ticipants tested positive: 28% in the lottery arm and 23% in the 
fixed-incentive arm.
The estimated relative proportion achieving SVR was not sig-
nificantly different between those who had and did not have a 
positive urine test at baseline or the last screen (PR = 1.13; 95% 
CI, 0.83–1.35). Likewise, the baseline toxicology result was not 
associated with achieving >90% HCV medication adherence 
(PR = 1.09; 95% CI, 0.48–1.51).
DISCUSSION
Financial incentives to encourage participation and adherence 
in HCV care among patients with a history of substance abuse 
were found to be feasible in this pragmatic pilot study. More 
than 90% of treatment-related visits were attended, and there 
was a low rate of study withdrawal. In addition, we observed 
high rates of both adherence to HCV DAA medication and care 
visits, with on average over 90% of prescribed doses of sofos-
buvir-containing regimens taken during the 12-week course of 
therapy, according to electronic medication monitoring. Given 
this, it is unsurprising that 92% of participants achieved SVR. 
Most importantly, study participants found the study proce-
dures and both financial incentives acceptable and feasible.
Rates of HCV-related clinical care and medication adher-
ence and SVR achievement were similar with the 2 strategies 
Table 2. Scheduled Visit Attendance
Lottery Fixed Overall P Value
Weed 2 Visit, n 19 10 29 .592
Attended 17 (89%) 8 (80%) 25 (86%)
Missed Visit 2 (11%) 2 (20%) 4 (14%)
Week 4 Visit, n 21 23 44 .222
Attended 19 (90%) 23 (100%) 42 (95%)
Missed Visit 2 (10%) 0 (0%) 2 (5%)
Week 6 Visit, n 12 6 18 >.999
Attended 12 (100%) 6 (100%) 18 (100%)
Week 8 Visit, n 15 14 29 >.999
Attended 13 (87%) 13 (93%) 26 (90%)
Missed Visit 2 (13%) 1 (7%) 3 (10%)
Week 12 Visit, n 30 27 57 .599
Attended 29 (97%) 25 (93%) 54 (88%)
Missed Visit 1 (3%) 2 (7%) 3 (5%)
Week 24 Visit, n (SVR) 31 28 59 >.999
Attended 27 (87%) 25 (89%) 52 (88%)
Missed Visit 4 (13%) 3 (11%) 7 (12%)
















n = 30* n = 28
fixed
Figure 2. Adjudicated analysis of hepatitis C virus medication adherence (elec-
tronic cap). *One lottery arm participant was excluded from the adjudicated elec-
tronic medication cap analyses due to inconsistent use of the electronic cap during 
treatment (participant was also using a pillbox).
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of financial incentives tested: 1 based on a lottery and the other 
a fixed schedule of payments. There were no significant differ-
ences between the study arms in the proportion who dropped 
out or were lost to follow-up, suggesting that both strategies 
were acceptable to patients. Furthermore, under the conditions 
studied, the costs of each approach were similar.
Because the convenience, tolerability, and potency of treat-
ment for HCV have increased, it can be argued that there is little 
need to incentivize adherence to HCV medications or clinical 
supervision. However, as HCV care expands to include those 
who were previously considered poor candidates for treatment, 
including those with active substance use and mental health 
disorders, the extremely high SVR rates seen in clinical trials of 
these medications may be lower in more real-world conditions 
among patients faced with barriers to entering and persisting 
in care. Given the high cost of HCV DAAs, the investment of 
a fraction of this expense to support treatment adherence and 
completion for even a small number of patients at risk for viro-
logic failure may be cost-saving. It is notable that during this 
pilot, half of the participants were actively using substances of 
abuse at baseline.
Lottery-based incentives have been used to support a number 
of other health behaviors including smoking cessation, weight 
loss, cancer screening, and antiretroviral therapy. Moreover, 
these incentives may be particularly effective for individuals, 
such as those with serious substance use disorders, who tend 
toward risk-taking endeavors [29, 33]. In this pilot comparison 
with predictable financial incentives, the lottery-based strategy 
seemed to be as acceptable and effective for promoting HCV 
treatment. Qualitative data collected at the end of the trial found 
that participants from both study arms had favorable views of 
the financial incentives as a tool to support HCV treatment, and 
those in the lottery-based arm found the strategy to be novel 
and, even, fun.
In preparation for a future randomized controlled trial, the 
primary foci of this pilot study were to examine the feasibility 
of delivering financial incentives for HCV patients and patients 
with substance abuse issues and ensure that the study proce-
dures and incentives were acceptable to patients; therefore, 
all participants received financial incentives. The influence of 
financial incentives on the clinical outcomes of interest cannot 
be determined from this study, because there was no nonincen-
tivized control group. Any future randomized controlled trial 
should compare one of these financial strategies to standard of 
care in an appropriately at-risk population to determine the effi-
cacy and effectiveness of this intervention.
In addition to a design that precludes the determination of 
the effectiveness of financial incentives for HCV care and med-
ication adherence, the interpretation of this study should also 
take into account that it was conducted at a single academic 
medical facility in the southeastern United States and may not 
generalize to other settings and locations. For this preliminary 
investigation of financially incentivizing HCV care, we included 
patients with current and previous abuse of a variety of sub-
stances. The outcomes we observed may have been different in 
cohorts with higher rates of active abuse of cocaine, metham-
phetamines, and/or opiods. Likewise, in this relatively small 
pilot, opportunities for analyses by subgroups such as gender, 
ethinicity, and race were not possible. Furthermore, there are 
well described limitations of both pill count and electronic 
monitoring for estimating medication adherence [46]. We 
applied both a conservative (unadjudicated) and more liberal 
(adjudicated) approach to the analysis of electronic medication 
adherence data and found the differences between these analy-
ses to be small. Substance use was assessed by self-report, which 
may suffer from social desirability bias. Finally, although urine 
toxicology was performed, which is a strength, participants did 
not always provide a requested urine specimen at each visit and 
therefore there are missing data; however, 55 of 59 participants 
provided at least 1 single urine specimen for toxicology testing 
at some point during the trial.
CONCLUSIONS
In conclusion, 2 different incentive strategies were successfully 
implemented with patients with a history of substance use dis-
orders. High levels of adherence to newer DAAs for HCV and 
to HCV clinical care were observed. These results support the 
further testing of financial incentives for HCV treatment with 
a controlled design, especially in patients with substantial chal-
lenges to adherence due to substance abuse disorders.
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